for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd (ADR)

BGNE.O

Latest Trade

198.25USD

Change

1.85(+0.94%)

Volume

518,770

Today's Range

194.83

 - 

204.00

52 Week Range

108.00

 - 

204.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
196.40
Open
202.05
Volume
518,770
3M AVG Volume
8.19
Today's High
204.00
Today's Low
194.83
52 Week High
204.00
52 Week Low
108.00
Shares Out (MIL)
784.44
Market Cap (MIL)
12,558.47
Forward P/E
-15.05
Dividend (Yield %)
--

Next Event

Beigene Ltd at Biocentury China Healthcare Summit

Latest Developments

More

Beigene Says Brukinsatm Gets Approval From U.S FDA

Beigene Says FDA Grants Brukinsa Accelerated Approval To Treat Adult Patients With Mantle Cell Lymphoma

FDA Grants Accelerated Approval To Brukinsa Capsules For Treating Adult Patients With Mantle Cell Lymphoma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd (ADR)

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Industry

Biotechnology & Drugs

Contact Info

C/O Mourant Governance Services (Cayman)

94 Solaris Avenue, Camana Bay

+1.345.9494123

Executive Leadership

John Victor Oyler

Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

General Manager - China, President

Howard Liang

Chief Financial Officer and Chief Strategy Officer

Jane Huang

Chief Medical Officer, Hematology

Hing Ling Chau

Company Secretary

Key Stats

1.62 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.2K

2018

0.2K

2019(E)

0.4K
EPS (USD)

2016

-3.840

2017

-2.230

2018

-12.150

2019(E)

-13.173
Price To Earnings (TTM)
--
Price To Sales (TTM)
29.21
Price To Book (MRQ)
9.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.00
LT Debt To Equity (MRQ)
19.94
Return on Investment (TTM)
-43.49
Return on Equity (TTM)
-38.60

Latest News

Latest News

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

China-based drugmaker BeiGene Ltd on Friday priced its drug, Brukinsa, to treat a rare form of lymphoma at $12,935 for a 30-day supply.

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

BeiGene drug wins U.S. FDA approval for rare form of lymphoma

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China

Amgen Inc <AMGN.O> said on Thursday it will take a 20.5% stake in BeiGene Ltd <6160.HK> in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.

Amgen to take 20.5% stake in BeiGene to expand in China

Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up